Immune-mediated thrombotic thrombocytopenic purpura in childhood treated by caplacizumab, about 3 cases

Julie Boudali1, Benjamin Hallak2, Marie Haeck3

  • 1Department of Nephrology, CHRU Lille, Lille, France.

Journal of Nephrology
|February 22, 2021
PubMed

Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a rare disease in adults and exceptional in childhood. Caplacizumab has proven its effectiveness in the treatment of iTTP in adulthood in association with standard of care. Unfortunately, this treatment is restricted to adults. We report our experience in three children who were treated successfully with caplacizumab.